Article Text
Abstract
Aim: To assess the efficacy and safety of an intravitreal injection of bevacizumab (Avastin®) for myopic choroidal neovascularisation (mCNV).
Methods: Intravitreal bevacizumab (1 mg) was injected into eight eyes of eight patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fluorescein angiography findings were examined before and after treatment. The minimum follow-up time was 3 months.
Results: The mean BCVA was 0.26 before treatment and 0.51 at the last visit (p = 0.009). The BCVA improved to two or more lines in six eyes (75%) and remained the same in two eyes (25%). Leakage from the mCNV on fluorescein angiography decreased in seven eyes (87.5%). The choroidal neovascularisation area on fluorescein angiography (p = 0.049) and the foveal thickness on OCT images decreased significantly (p = 0.027) after the treatment. No major complications developed.
Conclusion: Intravitreal injection of bevacizumab seems to be an effective and safe treatment for mCNV.
- AMD, age-related macular degeneration
- BCVA, best-corrected visual acuity
- CNV, choroidal neovascularisation
- mCNV, myopic choroidal neovascularisation
- OCT, optical coherence tomography
- PDT, photodynamic therapy
- VEGF, vascular endothelial growth factor
Statistics from Altmetric.com
Footnotes
-
Published Online First 16 August 2006
-
This work was Supported by Health Sciences Research Grant from the Ministry of Health, Labor and Welfare, Japan. We have no proprietary interest in any aspect of this report.
-
Competing interests: None declared.